Vimizim

BioMarin Hit with DOJ Subpoena on Sponsored Testing for Rare Diseases
BioSpace
Tue, 02/27/24 - 11:31 am
Biomarin
SEC
DOJ
Vimizim
Naglazyme
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
Motley Fool
Sat, 02/25/17 - 03:19 pm
Biomarin
earnings
Vimizim
Kuvan
Naglazyme
The 5 Most Expensive Drugs in the World in 2015
Motley Fool
Sun, 08/16/15 - 10:32 am
drug pricing
Glybera
Soliris
Naglazyme
Vimizim
Elaprase
Shire
Biomarin
Alexion
uniQure
BioMarin and its patient coaches are ready to roll on Vimizim launch
Fierce Pharma
Mon, 02/17/14 - 07:48 pm
Biomarin
Vimizim
drug launches
FDA approves BioMarin's genetic disorder drug Vimizim
Yahoo/Reuters
Fri, 02/14/14 - 06:29 pm
Biomarin
FDA
Vimizim
Morquio A Syndrome
FDA panel backs approval of BioMarin's Morquio A Syndrome drug
Yahoo/Reuters
Tue, 11/19/13 - 04:18 pm
FDA
advisory panels
Biomarin
Morquio A Syndrome
Vimizim
BioMarin shares rally as FDA mutes criticism of rare disorder drug
MarketWatch
Sat, 11/16/13 - 01:18 pm
Biomarin
Morquio A Syndrome
Vimizim
BioMarin's Morquio A drug confers "modest" benefit -FDA review
Yahoo/Reuters
Fri, 11/15/13 - 09:04 am
Biomarin
Morquio A Syndrome
FDA
Vimizim
3 Orphan Drugmakers to Watch
Motley Fool
Wed, 10/23/13 - 08:43 am
orphan drugs
Biomarin
GSK
Vimizim
Tafinlar
Mekinist
Myozyme
Cerazyme
Sanofi
5 Things You Need to Know From BioMarin's R&D Day
Motley Fool
Thu, 09/19/13 - 03:09 am
R&D
Biomarin
Vimizim
BMN-701
BMN-111
BMN-673
3 PDUFA Dates That Will Kick Off 2014
Motley Fool
Tue, 08/27/13 - 05:34 pm
FDA
diabetes
Forixga
Bristol-Myers Squibb
AstraZeneca
Biomarin
Vimizim
Amylin
metreleptin
FDA delays review of BioMarin's Vimizim by three months
The Fly on the Wall
Thu, 05/30/13 - 11:33 am
Vimizim
FDA
Biomarin